Literature DB >> 29848015

Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.

Seon Jeong Oh1, Eun Young Chae1, Joo Hee Cha1, Hee Jung Shin1, Woo Jung Choi1, Hak Hee Kim1.   

Abstract

OBJECTIVE: To evaluate the impact of background parenchymal enhancement (BPE) on breast MRI and pathological tumor responses to neoadjuvant chemotherapy (NAC) in breast cancer patients.
METHODS: A panel of 372 MRI from 186 pathologically confirmed breast cancer patients who underwent breast MRI before and after NAC were selected. BPE was classified into four categories before and after NAC. The association between BPE and the pathological tumor response to NAC, recurrence-free survival (RFS) and molecular subtypes were analyzed. We also evaluated the associations between the baseline BPE before NAC and menopausal status or mammographic parenchymal density.
RESULTS: Baseline BPE did not differ significantly according to the pathological tumor response to NAC (p = 0.2019). However, changes in BPE after NAC were significantly greater in the pathological complete remission (pCR) group than in the non-pCR group (p = 0.0008). There was no statistically significant association between BPE and RFS or molecular subtypes. The baseline BPE of pre-menopausal females (2.77 ± 0.86) were greater than those of post-menopausal females (2.05 ± 0.69), with statistical significance (p < 0.0001). Baseline BPE showed no significant difference according to mammographic parenchymal density.
CONCLUSION: The degree of BPE reduction in breast MRI correlates with the pathological tumor response to NAC in breast cancer patients. No significant difference in BPE was observed according to RFS or molecular subtypes of tumors. Advances in knowledge: This study suggests that the change in BPE may have potential as a biomarker of tumor response in breast cancer patients receiving NAC.

Entities:  

Mesh:

Year:  2018        PMID: 29848015      PMCID: PMC6209459          DOI: 10.1259/bjr.20170550

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  20 in total

Review 1.  The role of neoadjuvant chemotherapy for breast cancer treatment.

Authors:  Tadashi Ikeda; Hiromitsu Jinno; Akira Matsu; Shigeru Masamura; Masaki Kitajima
Journal:  Breast Cancer       Date:  2002       Impact factor: 4.239

2.  Defining the benefits of neoadjuvant chemotherapy for breast cancer.

Authors:  Anne F Schott; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

3.  Background parenchymal enhancement at breast MR imaging and breast cancer risk.

Authors:  Valencia King; Jennifer D Brooks; Jonine L Bernstein; Anne S Reiner; Malcolm C Pike; Elizabeth A Morris
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

4.  Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging.

Authors:  Simone Schrading; Christiane K Kuhl
Journal:  Radiology       Date:  2015-07-14       Impact factor: 11.105

5.  Does background parenchymal enhancement on MRI affect the rate of positive resection margin in breast cancer patients?

Authors:  S Y Park; D K Kang; T H Kim
Journal:  Br J Radiol       Date:  2014-11-27       Impact factor: 3.039

6.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

Authors:  N Wolmark; J Wang; E Mamounas; J Bryant; B Fisher
Journal:  J Natl Cancer Inst Monogr       Date:  2001

7.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

Authors:  J A van der Hage; C J van de Velde; J P Julien; M Tubiana-Hulin; C Vandervelden; L Duchateau
Journal:  J Clin Oncol       Date:  2001-11-15       Impact factor: 44.544

Review 8.  Update on locally advanced breast cancer.

Authors:  Sharon H Giordano
Journal:  Oncologist       Date:  2003

9.  Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers?

Authors:  Ji Youn Kim; Sung Hun Kim; Yun Ju Kim; Bong Joo Kang; Yeong Yi An; A Won Lee; Byung Joo Song; Yong Soo Park; Han Bi Lee
Journal:  Magn Reson Imaging       Date:  2014-08-29       Impact factor: 2.546

10.  Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.

Authors:  Ji Soo Choi; Eun Sook Ko; Eun Young Ko; Boo-Kyung Han; Seok Jin Nam
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more
  11 in total

Review 1.  Background parenchymal enhancement on breast MRI: A comprehensive review.

Authors:  Geraldine J Liao; Leah C Henze Bancroft; Roberta M Strigel; Rhea D Chitalia; Despina Kontos; Linda Moy; Savannah C Partridge; Habib Rahbar
Journal:  J Magn Reson Imaging       Date:  2019-04-19       Impact factor: 4.813

2.  Background parenchymal enhancement and breast cancer: a review of the emerging evidences about its potential use as imaging biomarker.

Authors:  Rossella Rella; Andrea Contegiacomo; Enida Bufi; Sara Mercogliano; Paolo Belli; Riccardo Manfredi
Journal:  Br J Radiol       Date:  2020-10-15       Impact factor: 3.039

3.  Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.

Authors:  Natsuko Onishi; Wen Li; David C Newitt; Roy J Harnish; Fredrik Strand; Alex Anh-Tu Nguyen; Vignesh Amal Arasu; Jessica Gibbs; Ella F Jones; Lisa J Wilmes; John Kornak; Bonnie N Joe; Elissa R Price; Haydee Ojeda-Fournier; Mohammad Eghtedari; Kathryn W Zamora; Stefanie Woodard; Heidi R Umphrey; Michael T Nelson; An L Church; Patrick J Bolan; Theresa Kuritza; Kathleen Ward; Kevin Morley; Dulcy Wolverton; Kelly Fountain; Dan Lopez Paniagua; Lara Hardesty; Kathleen R Brandt; Elizabeth S McDonald; Mark Rosen; Despina Kontos; Hiroyuki Abe; Deepa Sheth; Erin Crane; Charlotte Dillis; Pulin Sheth; Linda Hovanessian-Larsen; Dae Hee Bang; Bruce Porter; Karen Y Oh; Neda Jafarian; Luminita A Tudorica; Bethany Niell; Jennifer Drukteinis; Mary S Newell; Marina E Giurescu; Elise Berman; Constance D Lehman; Savannah C Partridge; Kimberly A Fitzpatrick; Marisa H Borders; Wei Tse Yang; Basak Dogan; Sally Hayward Goudreau; Thomas Chenevert; Christina Yau; Angela DeMichele; Donald A Berry; Laura J Esserman; Nola M Hylton
Journal:  Radiology       Date:  2021-08-24       Impact factor: 29.146

Review 4.  Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.

Authors:  Weilin Xu; Xiu Chen; Fei Deng; Jian Zhang; Wei Zhang; Jinhai Tang
Journal:  Onco Targets Ther       Date:  2020-06-22       Impact factor: 4.147

5.  Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.

Authors:  Jing-Min Dong; Hong-Xia Wang; Xiao-Fei Zhong; Kun Xu; Jia Bian; Yan Feng; Liang Chen; Lin Zhang; Xia Wang; De-Jing Ma; Bin Wang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

6.  Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.

Authors:  Mirella L Altoe; Kevin Kalinsky; Alessandro Marone; Hyun K Kim; Hua Guo; Hanina Hibshoosh; Mariella Tejada; Katherine D Crew; Melissa K Accordino; Meghna S Trivedi; Dawn L Hershman; Andreas H Hielscher
Journal:  Breast Cancer Res       Date:  2021-01-31       Impact factor: 6.466

7.  Breast cancer and background parenchymal enhancement at breast magnetic resonance imaging: a meta-analysis.

Authors:  Na Hu; Jinghao Zhao; Yong Li; Quanshui Fu; Linwei Zhao; Hong Chen; Wei Qin; Guoqing Yang
Journal:  BMC Med Imaging       Date:  2021-02-19       Impact factor: 1.930

8.  Contrast-Enhanced Spectral Mammography-Based Radiomics Nomogram for the Prediction of Neoadjuvant Chemotherapy-Insensitive Breast Cancers.

Authors:  Zhongyi Wang; Fan Lin; Heng Ma; Yinghong Shi; Jianjun Dong; Ping Yang; Kun Zhang; Na Guo; Ran Zhang; Jingjing Cui; Shaofeng Duan; Ning Mao; Haizhu Xie
Journal:  Front Oncol       Date:  2021-02-22       Impact factor: 6.244

Review 9.  Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.

Authors:  Ella F Jones; Deep K Hathi; Rita Freimanis; Rita A Mukhtar; A Jo Chien; Laura J Esserman; Laura J Van't Veer; Bonnie N Joe; Nola M Hylton
Journal:  Cancers (Basel)       Date:  2020-06-09       Impact factor: 6.575

10.  Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.

Authors:  Wen Li; David C Newitt; Jessica Gibbs; Lisa J Wilmes; Ella F Jones; Vignesh A Arasu; Fredrik Strand; Natsuko Onishi; Alex Anh-Tu Nguyen; John Kornak; Bonnie N Joe; Elissa R Price; Haydee Ojeda-Fournier; Mohammad Eghtedari; Kathryn W Zamora; Stefanie A Woodard; Heidi Umphrey; Wanda Bernreuter; Michael Nelson; An Ly Church; Patrick Bolan; Theresa Kuritza; Kathleen Ward; Kevin Morley; Dulcy Wolverton; Kelly Fountain; Dan Lopez-Paniagua; Lara Hardesty; Kathy Brandt; Elizabeth S McDonald; Mark Rosen; Despina Kontos; Hiroyuki Abe; Deepa Sheth; Erin P Crane; Charlotte Dillis; Pulin Sheth; Linda Hovanessian-Larsen; Dae Hee Bang; Bruce Porter; Karen Y Oh; Neda Jafarian; Alina Tudorica; Bethany L Niell; Jennifer Drukteinis; Mary S Newell; Michael A Cohen; Marina Giurescu; Elise Berman; Constance Lehman; Savannah C Partridge; Kimberly A Fitzpatrick; Marisa H Borders; Wei T Yang; Basak Dogan; Sally Goudreau; Thomas Chenevert; Christina Yau; Angela DeMichele; Don Berry; Laura J Esserman; Nola M Hylton
Journal:  NPJ Breast Cancer       Date:  2020-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.